Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics Inc. exhibits a promising financial outlook, with projected risk-adjusted revenues from hypercortisolism expected to increase significantly, reaching $698 million by 2030, compared to just $68 million in 2026. The company has established a strong prescriber and patient base for its product, Korlym, and anticipates a successful launch of the selective cortisol modulator, relacorilant, with a substantially increased probability of success at 90%. Additionally, there is potential for considerable revenue growth from the CATALYST study, which could contribute an estimated $400 million to $500 million annually, particularly with successful market adoption in challenging patient populations.

Corcept Therapeutics faces significant operational challenges that may lead to lower revenue in 2025, particularly due to ongoing issues in managing demand for its drug, Korlym, which could impact the company's financial performance. There is a concerning lack of awareness and data among prescribing doctors, with 70% of surveyed physicians citing these factors as barriers to adoption, undermining the potential market for Corcept's therapeutic offerings. Additionally, the discrepancy between the clinical trial prevalence of hypercortisolism and the perceptions of endocrinologists points to a substantial gap in understanding that could further impede the growth of Korlym within the target patient population.